BPC-157 has a big reputation online as a "healing peptide" for tendons, joints and the gut. The research behind that reputation is mostly in animals. This post walks through what studies actually show, what they do not show, and where BPC-157 stands with the FDA in late 2026.
Key takeaways
- BPC-157 is a lab-made chain of 15 amino acids based on a piece of a protein found in gastric juice.
- Most research is in rats and cells. A 2025 systematic review found only one human study in orthopedic and sports medicine, with 12 patients.
- It is not FDA-approved for any use. Human safety is largely unknown.
- A July 2026 FDA advisory committee narrowly recommended allowing it in pharmacy compounding. That vote is advisory, and FDA had not finalized any change as of late October 2026.
- It is prohibited in sport under the WADA list.
What BPC-157 is
BPC stands for "body protection compound." BPC-157 is a synthetic peptide made of 15 amino acids, modeled on a fragment of a larger protein that researchers isolated from stomach juice. It does not exist as a standalone hormone or drug in the body the way insulin does.
Much of the early research came from one research group in Croatia, which published many animal studies over several decades. That is useful work, but having so much of a field come from one group is a reason to wait for independent confirmation.
What the animal research shows
In rats and lab models, researchers have reported that BPC-157 may:
- Speed healing of injured tendons, ligaments and muscles
- Protect the stomach and gut lining in injury models
- Affect blood vessel growth (angiogenesis) and blood flow
- Interact with nitric oxide and other signaling pathways
A 2025 systematic review in HSS Journal looked at BPC-157 in orthopedic sports medicine. It found 36 studies, and 35 were preclinical (animal or lab). The animal studies generally reported faster healing and no acute toxicity. Animal results often do not carry over to people, though. Many treatments that work in rats fail in human trials.
What the human research shows
This is the short part.
| Type of evidence | What exists |
|---|---|
| Large randomized controlled trials | None published |
| Human studies in the 2025 orthopedic review | 1 retrospective review of 12 patients with knee pain |
| Registered clinical trials found by that review | 1 phase I trial, status unknown |
| Long-term human safety data | None |
In that small knee study, 7 of 12 people reported relief lasting more than 6 months. The review authors rated it as low-level evidence (level IV/V) because it had no control group and looked back at past records. They concluded it cannot support clinical recommendations and stated that "no clinical safety data were found." A small pilot study of intravenous BPC-157 safety in a handful of people has also been published, but it was not designed to show benefit.
In plain terms: we do not know whether BPC-157 helps people heal, and we do not have good data on how safe it is.
Safety questions
Because human data are so thin, safety concerns are mostly theoretical or about product quality:
- Blood vessel growth. Animal studies suggest BPC-157 promotes angiogenesis. That could help healing, but researchers have raised the question of whether it could also feed the blood supply of existing tumors. This has not been studied in people.
- Immune reactions. FDA has noted possible immunogenicity and problems characterizing the peptide and its impurities.
- Unknown products. "Research use only" BPC-157 sold online is not made for human use. Contents, purity, sterility and dose can differ from the label. The HSS Journal review warned that unregulated products may be contaminated.
People who are pregnant or breastfeeding, have a history of cancer, or take blood thinners have extra reasons to stay cautious and talk to a provider.
Where BPC-157 stands with the FDA (October 2026)
The regulatory picture changed a lot in 2026, so here is a careful summary:
- Not FDA-approved. No BPC-157 product has gone through FDA review for safety and effectiveness.
- Category 2 removal. FDA's compounding safety-risk page now lists the BPC-157 nomination as withdrawn by the nominators. FDA's page still describes concerns about immunogenicity, impurities and limited safety information.
- Advisory committee vote. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee considered BPC-157 for ulcerative colitis and voted narrowly (8-6, with one abstention, according to a law-firm summary) to recommend adding it to the 503A bulks list. FDA staff scientists had recommended against it, citing weak clinical data, batch quality and immune-reaction risk.
- Not final. The vote is non-binding. As of mid-October 2026, HHS and FDA had sent an "interim access policy" for certain peptides to the White House budget office for review, but it had not been issued. Legal analysts noted that no peptide had yet been added to the bulks list.
Rules may change quickly. Our posts on FDA bulk drug substance categories and whether peptides are legal in the US explain the background. Even if compounding becomes allowed, that would not make BPC-157 FDA-approved or proven to work.
Sports and testing
The 2026 WADA Prohibited List names BPC-157 under S0, non-approved substances, prohibited at all times. Tested athletes should not use it. See our post on peptides and WADA.
If you are dealing with an injury
The best-supported steps for tendon, joint and muscle injuries are still a proper diagnosis, physical therapy, gradual loading, sleep and nutrition. If you are curious about BPC-157, bring it up with a licensed provider. Ask what is known, what is not, and how a product would be sourced. Our telehealth guide can help you find one.
The bottom line
BPC-157 has interesting animal research and almost no human evidence. It is not FDA-approved, human safety is largely unknown, and a 2026 advisory vote did not change that. Treat it as an open research question rather than a proven healing tool.
Sources
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- Holland & Knight: Peptides at a Crossroads (October 2026)
- World Anti-Doping Agency: The Prohibited List (2026)
Frequently asked questions
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any use. A July 2026 FDA advisory committee voted to recommend adding it to the list of substances that pharmacies may compound, but that vote is advisory and does not make it an approved drug.
How much human research is there on BPC-157?
Very little. A 2025 systematic review in HSS Journal found 36 studies on BPC-157 for orthopedic and sports medicine, and only one was in people: a small retrospective review of 12 patients with knee pain. Most of what is known comes from rats and lab dishes.
Is BPC-157 allowed in sports?
No. The 2026 WADA Prohibited List names BPC-157 as an example of a non-approved substance under section S0, which is prohibited at all times for athletes covered by the code.